Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 5/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20370587 | 0.95 | RAB9A (0.39) | RAB9ACNR2CNR1FFAR4MTNR1A | |
| SCHEMBL19855144 | 0.89 | RAB9A (0.46) | RAB9AALDH1A1LMNAMAPTITGB3 | |
| SCHEMBL19856046 | 0.88 | RAB9A (0.48) | RAB9ACNR2ALDH1A1LMNAMAPT | |
| SCHEMBL19854954 | 0.88 | RAB9A (0.39) | RAB9ACNR2CNR1FFAR4MTNR1A | |
| SCHEMBL20370574 | 0.88 | RARA (0.40) | RAB9ACNR2FFAR4ALDH1A1ITGB3 | |
| SCHEMBL20370590 | 0.87 | RAB9A (0.38) | RAB9ACNR2CNR1FFAR4MTNR1A | |
| SCHEMBL19856045 | 0.86 | RAB9A (0.46) | RAB9ACNR2ALDH1A1LMNAMAPT | |
| SCHEMBL20370471 | 0.85 | SPHK1 (0.40) | FFAR4ALDH1A1LMNAMAPT | |
| SCHEMBL19854951 | 0.85 | SPHK1 (0.40) | FFAR4ALDH1A1LMNAMAPTITGB3 | |
| SCHEMBL19854074 | 0.85 | RAB9A (0.39) | RAB9AFFAR4PTPN11ALDH1A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214615-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT | JNC CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| US-10662379-B2 | Polymerizable polar compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2020-05-26 | — | — | US | disclosed |
| US-20180195005-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20180195005-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-07-12 | — | — | US | disclosed |
| WO-2018025974-A1 | LIQUID-CRYSTAL DISPLAY ELEMENT AND DISPLAY DEVICE | JNC株式会社 | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180195005-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, MBD2, PAXBP1 | RAB9A 4014/4885CNR2 1030/4885CNR1 589/4885 |
| US-10662379-B2 | Polymerizable polar compound, liquid crystal composition and liquid crystal display device | SP1, MBD2, PAXBP1 | RAB9A 4014/4885CNR2 1030/4885CNR1 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.